`

Tagged: drug approval

RWE can accelerate approval timelines and reduce drug development costs as long as sponsor companies carefully uphold established evidence and engage in early dialogue with the FDA.

January 19th, 2023 | drug approval

Real-world evidence (RWE) is increasingly important in clinical trial design and drug approval. RWE is clinical evidence related to patient health status and treatment safety and efficacy that are generated in clinical practice. BBCR’s team understands the role RWE plays for Natural History in Rare Diseases. We invite you to be in touch to learn […]

Getting More Drugs Approved for Rare Diseases

July 3rd, 2019 | drug approval

Pin It on Pinterest